Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Andabaka, Tea ^a   Nickerson, Jason W ^b   Rojas Reyes, Maria Ximena ^c   Rueda, Juan David ^c   Bacic Vrca, Vesna ^d   Barsic, Bruno ^e  

^a UNIVERSITY OF SPLIT   (Croatia)

^b UNIVERSITY OF OTTAWA   (Canada)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d University of Zagreb School of Medicine   (Croatia)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; ANTIVIRUS AGENT;

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; INFANT; NEWBORN; PRESCHOOL CHILD; STATISTICS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84881346119     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006602.pub4     Document Type: Review

References (112)

1. Abarca K, Jung E, Fernandez P, Zhao L, Harris B, Connor EM, et al.Motavizumab Study Group. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatric Infectious Disease Journal 2009;28(4):267-72.
2. Bentley A, Filipovic I, Gooch K, Buesch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK. Thorax 2011;66(Suppl 4):A136-7.
3. Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, et al.Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a non-inferiority trial. Pediatrics 2010;125(1):e35-51.
4. Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Italian Journal of Pediatrics 2009;35:4. [DOI: 10.1186/1824-7288-35-4].
5. Chiroli S, Macagno F, Lucioni C. Cost-efficacy analysis of palivizumab in the prevention of respiratory syncytial virus infections in young children with hemodynamically significant congenital heart disease. Italian Journal of Pediatrics 2005;31:188-94.
6. ElHassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Archives of Pediatrics and Adolescent Medicine 2006;160:1070-6.
7. Embleton ND, Dharmaraj ST, Deshpande S. Cost-effectiveness of palivizumab in infancy. Expert Review of Pharmacoeconomics and Outcomes Research 2007;7(5):445-58.
8. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al.Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics 2003;143(4):532-40.
9. Feltes TF, Sondheimer HM, Tulloh RMR, Harris BS, Jensen KM, Losonsky GA, et al.Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatric Research 2011;70(2):186-91.
10. Fernandez P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, et al.Motavizumab Study Group. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatrics 2010;10:38-50.
11. Garcia-Altes A, Paladio N, Tebe C, Pons JMV. Cost-effectiveness analysis of the administration of palivizumab as prophylaxis of severe bronchiolitis due to respiratory syncytial virus [Anàlisi cost-efectivitat de l'administració del palivizumab en la profilaxi de les bronquiolitis greus per virus respiratori sincicial]. Pediatria Catalana 2010;70:57-64.
12. Hampp C, Kauf TL, Saidi A, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab from the perspective of a Southern US medicaid agency. Value in Health 2009;12(7):A301-2.
13. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Archives of Pediatrics and Adolescent Medicine 2011;165(6):498-505.
14. Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Canadian Journal of Cardiology 2011;27:523.e11-.e15.
15. Human DG, Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Cardiology in the Young 2010;20(Suppl 1):30.
16. Hascoet JM, Fagnani F, Charlemagne A, Vieux R, Roze JC. Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting [Aspects methodologiques de l'evaluation economique du medicament en pediatrie: exemple de la prophylaxie de l'infection a VRS en France]. Archives de Pediatrie 2008;15:1739-48.
17. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.
18. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104(3):419-27.
19. Kang HY, Kim HS, Choi JY, Kim YH. Cost-effectiveness analysis of palivizumab in the prevention of respiratory syncytial virus infection in Korean children with congenital heart disease. Value in Health 2009;12(7):A424.
20. Lanctot KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, et al.The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Current Medical Research and Opinion 2008;24(11):3223-37.
21. Carbonell-Estrany X, Lázaro y de Mercado P. Health economics and RSV. Paediatric Respiratory Reviews 2009;10(Suppl 1):12-3.
22. Lazaro y de Mercado P, Figueras Aloy J, Domenech Martinez E, Echaniz Urcelay I, Closa Monasterolo R, Wood MA. The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain [La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España]. Anales de Pediatria 2006;65(4):316-24.
23. Lazaro y de Mercado P, Figueras J, Domenech E, Closa R, Echaniz I, Wood MA, et al.Cost-effectiveness of palivizumab in preventing respiratory syncytial virus in premature infants and children with chronic lung disease in Spain [Coste-efectividad de palivizumab para prevenir el virus respiratorio sincitial en niños prematuros y niños con enfermedad pulmonar crónica en España]. Pharmacoeconomics - Spanish Research Articles 2007;4(2):57-68.
24. Lofland JH, Touch SM, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, et al.Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clinical Therapeutics 2000;22(11):1357-69.
25. Mayen-Herrera E, Buesch K, Cortina D. Economic evaluation of the use of palivizumab as prophylactic treatment for the reduction of complications associated with respiratory syncytial virus in pre-term patients. Value in Health 2011;14(7):A565-6.
26. Neovius K, Buesch K, Neovius M. Burden of respiratory syncytial virus (RSV) and potential impact of prophylaxis in infants in Sweden: a cost-effectiveness analysis. Acta Paediatrica 2010;99:96-7.
27. Neovius K, Buesch K, Sandstrom K, Neovius M. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatrica 2011;100(10):1306-14. [DOI: 10.1111/j.1651-2227.2011.02309.x].
28. Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25(1):55-71.
29. Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. Journal of Medical Economics 2009;12(4):291-300.
30. Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. Journal of Medical Economics 2009;12(4):301-8.
31. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. European Journal of Health Economics 2010;11:105-15.
32. Ravasio R, Lucioni C, Chirico G. Cost-effectiveness analysis of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infections among premature infants, with different gestational ages [Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale]. PharmacoEconomics - Italian Research Articles 2006;8(2):105-17.
33. Raya Ortega L, Marquez Calderon S, Navarro Caballero JA, Villegas Portero R. Cost-effectiveness of palivizumab in the prevention of hospital admissions for syncytial respiratory virus in pre-term babies born at 32 to 35 weeks. Sevilla: Andalusian Agency for Health Technology Assessment (AETSA) 2006;Informe 14:1-47.
34. Resch B, Gusenleitner W, Nuijten MJC, Lebmeier M, Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clinical Therapeutics 2008;30(4):749-60.
35. Resch B, Sommer C, Nuijten MJC, Seidinger S, Walter E, Schoellbauer V, et al.Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatric Infectious Disease Journal 2012;31(1):e1-8.
36. Rietveld E, Steyerberg EW, Polder JJ, Veeze HJ, Vergouwe Y, Huysman MWA, et al.Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Archives of Disease in Childhood 2010;95:493-8.
37. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalisations in premature infants in Germany. European Journal of Pediatrics 2003;162:237-44.
38. Salinas-Escudero G, Martinez-Valverde S, Reyes-Lopez A, Garduno-Espinosa J, Munoz-Hernandez O, Granados-Garcia V, et al.Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico. Salud Publica de Mexico 2012;54(1):47-59.
39. Smart KA, Paes BA, Lanctot KL. Changing costs and the impact on RSV prophylaxis. Journal of Medical Economics 2010;13(4):705-8.
40. Subramanian SKN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al.MEDI-493 Study Group. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatric Infectious Disease Journal 1998;17(2):110-5.
41. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctot KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. Journal of Medical Economics 2009;12(4):361-70.
42. Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, et al.Cost-effectiveness of palivizumab in New Zealand. Journal of Paediatrics and Child Health 2002;38:352-7.
43. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technology Assessment 2011;15(5):1-124. [DOI: 10.3310/hta15050].
44. Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by medicaid in the United States. Journal of Medical Economics 2012;15(5):997-1018.
45. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114(6):1606-11.
46. Banerji A, Lanctot KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, et al.Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatric Infectious Disease Journal 2009;28(8):702-6.
47. Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. Journal of Managed Care Pharmacy 2010;16(1):15-22.
48. Chan PWK, Abdel-Latif MEA. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatrica 2003;92(4):481-5.
49. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Archives of Disease in Childhood 2000;83(4):313-6.
50. Datar M, Banahan BF. Palavizumab (Synagis) use and outcomes among medicaid beneficiaries. Value in Health 2012;15(4):A58-9.
51. Farina D, Rodriguez SP, Bauer G, Novali L, Bouzas L, Gonzalez H, et al.Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatric Infectious Disease Journal 2002;21(4):287-91.
52. Korbal P, Mikolajczak A, Szymanski W. Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams [Ocena skutecznosci stosowania uodpornienia biernego przeciwko wirusom syncytium nablonka oddechowego (RSV) preparatem Synagis w grupie wczesniakow z masa urodzeniowa ciala ponizej 1000 gramow]. Ginekologia Polska 2003;74(10):1154-9.
53. Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value in Health 2010;13(1):77-86.
54. Lapena Lopez de Armentia S, Robles Garcia MB, Martinez Badas JP, Castanon Fernandez L, Mallo Castano L, Herrero Mendoza B, et al.Potential impact and cost-efficacy of bronchiolitis prophylaxis with palivizumab in preterm infants with a gestational age of less than 33 weeks. Anales de Pediatria 2003;59(4):328-33.
55. Lee SL, Etches P, Robinson JL. Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta. Paediatrics and Child Health 2001;6(8):525-32.
56. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clinical Therapeutics 1999;21(4):752-66.
57. Marques T, Cardoso K. Palivizumab prophylaxis: comparative study between immunized and non immunized infants admitted with respiratory syncytial virus infection. Early Human Development 2010;86(Suppl):123-4.
58. Martinez JL. Palivizumab in preventing infection caused by respiratory syncitial virus (RSV) [Palivizumab en la prevención de infección por virus respiratorio sincicial]. Revista Chilena de Pediatria 2002;73(1):9-14.
59. McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatric Pulmonology 2002;34(4):262-6.
60. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects - hospitalisations and costs. Acta Paediatrica 2006;95(4):404-6.
61. Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, et al.Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrobial Agents and Chemotherapy 1999;43(5):1183-8.
62. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. Journal of Paediatrics and Child Health 2000;36:422-7.
63. Parmigiani S, Ubaldi A, Capuano C, Magini GM, Bianchi ME. Palivizumab in infants with gestational age ≤ 28 weeks and bronchopulmonary dysplasia. Acta Bio-Medica de l Ateneo Parmense 2001;72(5-6):109-13.
64. Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiology in the Young 2005;15(3):251-5.
65. Reeve CA, Whitehall JS, Buetnner PG, Norton R, Reeve DM, Francis F. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Journal of Paediatrics and Child Health 2006;42(5):253-8.
66. Rodriguez SP, Farina D, Bauer G. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis. Pediatric Infectious Disease Journal 2008;27(7):660-1.
67. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children. Archives of Pediatrics and Adolescent Medicine 2002;156(12):1251-5.
68. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Archives of Pediatrics and Adolescent Medicine 2000;154(1):55-61.
69. Strutton DR, Stang PE. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making. Journal of Pediatrics 2003;143(Suppl 5):157-62.
70. Takeuchi Y, Cho H, Yamashita Y, Mishiku Y, Nakao A, Aso T, et al.Safety and pharmacokinetics of palivizumab, administered in infants with a history of prematurity or chronic lung disease. Japanese Journal of Chemotherapy 2002;50(4):215-22.
71. Vann JJ, Feaganes J, Wegner S. Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab. Pharmacoeconomics 2007;25(9):793-800.
72. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Clinical Governance: an International Journal 2009;14(2):156-8.
73. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technology Assessment 2008;12(36):1-86.
74. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, et al.Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid program. Pediatrics 2004;114(6):1612-9.
75. Wendel B, Jorden J. Financial impact of a clinically based palivizumab prior authorization program in a medicaid population. Journal of the American Pharmacists Association 2010;50(2):231.
76. NCT00233064. A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease. http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00233064 (accessed 27 July 2012).
77. NCT00240929. A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis), A Humanized Respiratory Syncytial Virus Monoclonal Antibody, in Children With a History of Prematurity. http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00240929 (accessed 27 July 2012).
78. NTR1023. Effect of palivizumab on respiratory syncytial virus-associated burden of disease: a randomized controlled trial. http://apps.who.int/trialsearch/Trial.aspx?TrialID=NTR1023 (accessed 27 July 2012).
79. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124(6):1694-701.
80. Arms JL, Ortega H, Reid S. Chronological and clinical characteristics of apnea associated with respiratory syncytial virus infection: a retrospective case series. Clinical Pediatrics 2008;47(9):953-8.
81. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
82. Centers for Disease Control and Prevention. Respiratory syncytial virus: United States, July 2007-June 2011. Morbidity and Mortality Weekly Report 2011;60(35):1203-6. [PUBMED: 21900874].
83. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clinical Microbiology Reviews 1999;12(2):298-309. [PUBMED: 0194461].
84. Drummond MF, Jefferson TO, The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313(7052):275-83.
85. United States Food, Drug Administration. Safety Alerts for Human Medical Products > Synagis (palivizumab). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm155089.htm 2009 (accessed 5 February 2013).
86. United States Food, Drug Administration. Background Package for BLA 125283 motavizumab. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM213825.pdf 2010 (accessed 5 February 2013).
87. Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. Journal of Epidemiology and Community Health 2005;59(7):586-90.
88. Glanville J, Kaunelis D, Mensinkai S. How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE. International Journal of Technology Assessment in Health Care 2009;25(4):522-9.
89. Golder S, McIntosh H, Duffy S, Glanville J, Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Information and Libraries Journal 2006;23(1):3-12.
90. Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows. -, 2008.
91. Hall CB, Hall WJ, Speers DM. Clinical and physiological manifestations of bronchiolitis and pneumonia. Outcome of respiratory syncytial virus. American Journal of Diseases of Children 1979;133(8):798-802.
92. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al.The burden of respiratory syncytial virus infection in young children. New England Journal of Medicine 2009;360(6):588-98.
93. Hall CB, Walsh EE. Respiratory syncytial virus. In: Feigin RD, et al. editor(s). Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 6th Edition. Vol. 2, Philadelphia: Saunders Elsevier, 2009:2462-87.
94. Hall CB. Respiratory syncytial virus. In: Mendell GL, Bennett JE, Dolin R editor(s). Mendell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th Edition. Vol. 2, Philadelphia: Churchill Livingstone Elsevier, 2010:2207-21.
95. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistence in meta-analyses. BMJ 2003;327(7414):557-60.
96. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Chichester, UK: Wiley-Blackwell, 2011.
97. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Chichester, UK: Wiley-Blackwell, 2011.
98. Jacobson PD, Kanna ML. Cost-effectiveness analysis in the courts: recent trends and future prospects. Journal of Health Politics, Policy and Law 2001;26(2):291-326.
99. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. Journal of Infectious Diseases 1997;176(5):1215-24.
100. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Chichester, UK: Wiley-Blackwell, 2011.
101. Mullins JA, Lamonte AC, Bresee JS, Anderson LJ. Substantial variability in community RSV season timing. Pediatric Infectious Disease Journal 2003;22(10):857-62.
102. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al.Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375(9725):1545-55.
103. Purcell K, Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatric Infectious Disease Journal 2004;23(5):418-23.
104. Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. Journal of Pediatrics 2009;155(5):728-33.
105. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK editor(s). Red Book: 2012 Report of the Committee on Infectious Diseases. 29th Edition. Elk Grove Village: Churchill Livingstone, 2012:609-18.
106. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
107. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD007743.pub3].
108. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. Journal of Infectious Diseases 2001;183(1):16-22.
109. Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatric Infectious Disease Journal 2003;22(Suppl 2):13-8.
110. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al.Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289(2):179-86.
111. Lozano JM, Escovar C, Vásquez V. Monoclonal antibodies for preventing respiratory syncytial virus infection. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006602.pub2].
112. Wang EEL, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001725.pub2].